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ABSTRACT
The methyl-CpG binding domain (MBD) family of
proteins was de®ned based on sequence similarity
in their DNA binding domains. In light of their high
degree of conservation, it is of inherent interest to
determine the genomic distribution of these
proteins, and their associated co-repressor com-
plexes. One potential determinant of speci®city
resides in differences in the intrinsic DNA binding
properties of the various MBD proteins. In this
report, we use a capillary electrophoretic mobility
shift assay (CEMSA) with laser-induced ¯uores-
cence (LIF) and neutral capillaries to calculate
MBD±DNA binding af®nities. MBD proteins were
assayed on pairs of methylated and unmethylated
duplex oligos corresponding to the promoter
regions of the BRCA1, MLH1, GSTP1 and p16INK4a
genes, and binding af®nities for each case were
calculated by Scatchard analyses. With the excep-
tion of mammalian MBD3 and Xenopus MBD3 LF, all
the MBD proteins showed higher af®nity for methy-
lated DNA (in the nanomolar range) than for
unmethylated DNA (in the micromolar range).
Signi®cant differences between MBD proteins in the
af®nity for methylated DNA were observed, ranging
within two orders of magnitude. By mutational
analysis of MBD3 and using CEMSA, we demon-
strate the critical role of speci®c residues within the
MBD in conferring selectivity for methylated DNA.
Interestingly, the binding af®nity of speci®c MBD
proteins for methylated DNA fragments from natur-
ally occurring sequences are affected by local
methyl-CpG spacing.
INTRODUCTION
Methylation at position 5 in cytosines is the most common
modi®cation of vertebrate genomes. In mammals, this modi-
®cation occurs almost exclusively in CpG dinucleotides. In
fact, 70% of all CpG dinucleotides are methylated in
mammals, with the exception of CpG islands, which are
CG-rich regions mostly coincident with the promoter of
protein-coding genes. In some circumstances, many CpG
islands become hypermethylated, resulting in gene silencing.
For instance, promoter hypermethylation of tumor suppressor
and DNA repair genes has been linked to cancer, and the study
of methylation changes in cancer constitutes an important
branch of study in cancer research (1). In this context, methyl-
CpG binding proteins appear to be central players in the
process of DNA methylation-dependent gene silencing (2).
This family of proteins takes its de®nition from the methyl-
CpG binding domain (MBD), the minimum portion with
speci®c af®nity for a single symmetrically methylated CpG
pair. The MBD was characterized by deletion studies of
MeCP2 (3). After the recognition of the MBD, four additional
genes were found to contain this domain, namely MBD1,
MBD2, MBD3 and MBD4 (4).
The biochemistry of MBD proteins has been studied at
different levels. In general, all MBD proteins, except MBD4,
have been reported to be associated with histone deacetylase
subunits as parts of large multisubunit complexes. For
instance, MBD3, the best characterized member of the MBD
family from a biochemical point of view, has been determined
as being a component of a complex called Mi-2/NURD that
contains a chromatin-remodeling ATPase, a histone deacety-
lase and other subunits (5). In mammals, MBD2 recruits the
MeCP1 histone deacetylase complex to DNA. The MeCP1
complex contains 10 major polypeptides, including MBD2
and all of the known NuRD components (6).
Some of the currently available data suggest that different
MBD protein-containing complexes are targeted speci®cally
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to different methylated promoters (2), although it is possible
that MBDs play no role in recognizing particular sequences. A
few studies support the notion of selectivity in the association
of MBD with particular promoters (7±9). However, the fact
that MBD2 knockout mice are viable has been interpreted as if
MBD proteins are at least partially redundant (10).
One of the still unresolved matters is the quantitative
contribution of the MBD proteins to the association of their
complexes with speci®c loci. While the MBD domain is
highly conserved, seemingly minor sequence differences
could produce alterations in af®nity for methylated DNA.
This could range from a high selectivity for methylated CpG
sites to a complete lack of binding. Supporting this notion,
DNase I footprinting of the MeCP2-MBD on DNA showed
that the methyl-CpG site was ~50% protected against DNase I
at an MBD concentration of 1.25 3 10±9 M, indicating a
dissociation constant close to this value (3). On the other hand,
electrophoretic mobility shift asssy (EMSA) and southwestern
analysis of mammalian MBD3 indicate that this protein cannot
speci®cally recognize methylated DNA (4), in contrast to its
amphibian homolog, which has been shown to bind methy-
lated DNA selectively (5). Quantitative characterization of the
binding to a single methyl-CpG pair of different MBD proteins
remains a key issue in the evaluation of their contribution to
the targeting to a promoter. Additional matters requiring
further characterization are the in¯uences of methyl-CpG
density and local sequence context on binding. For instance,
early results suggested that the MeCP1 complex, which was
later demonstrated to contain MBD2 (11), requires at least 12
consecutive CpGs to bind methylated DNA (12). Although
MBD2 has been demonstrated to recognize a single methy-
lated CpG pair, it is possible that MBD2 prefers more densely
methylated DNA. In other words, the density or distribution of
methyl-CpGs may in¯uence MBD2 binding. EMSAs and
southwestern analysis are suitable and convenient techniques
for qualitatively evaluating the association of MBDs with
DNA. However, additional techniques need to be used to
obtain reliable quantitative data on af®nities between MBD
proteins and methylated DNA. Capillary electrophoresis (CE)
has become a useful technique for measuring binding
constants. Compared with classical EMSA, in CE caging
effects are avoided and the conditions are closer to the
equilibrium; therefore, the fraction of protein±DNA com-
plexes separated during the electrophoretic procedure is
smaller than in EMSA (13).
To quantify protein±DNA binding af®nities, we have used a
modi®cation of the high-performance capillary electrophor-
esis-based method called CEMSA (capillary electrophoretic
mobility shift assay) (14). This modi®cation, termed
R-CEMSA (reverse capillary electrophoresis mobility shift
assay), is a quantitative, simple and rapid method for
calculating binding af®nities that employs neutral-coating
capillaries in order to avoid protein adsorption onto the
capillary walls. We make use of this quantitative method to
calculate the half-saturation concentration for DNA binding
proteins to evaluate the intrinsic contribution of the binding
properties of MBD proteins to their selective recruitment to
promoters. Two issues have been addressed, namely whether
different MBD proteins have signi®cantly different binding
af®nities for a model methylated sequence, and whether an
MBD protein is signi®cantly affected by local sequence
context and methyl-CpG density. Our results indicate that
CpG distribution along the sequence may in¯uence the
interaction of each MBD protein with DNA.
MATERIALS AND METHODS
Reagents
DNAs, purchased as single-stranded oligonucleotides
(Operon-Qiagen), were as follows: forward GAC, GAT
CCG ACG ACG ACG ACG ACG ACG ACG ACG ACG
ACG ACG ATC; reverse GAC, GAT CGT CGT CGT CGT
CGT CGT CGT CGT CGT CGT CGT CGG ATC; forward
GAM1 (monomethylated GAC), GAT CCG ACG ACG ACG
ACG AXG ACG ACG ACG ACG ACG ACG ATC; reverse
GAM1 (monomethylated GAC), GAT CGT CGT CGT CGT
CGT CGT XGT CGT CGT CGT CGT CGG ATC, where X
stands for 5-methyl-C; forward GSTP1, CCC TCC AGA AGA
GCG GCC GGC GCC GTG ACT CAG CAC TGG GGC GGA
GCG GG; reverse GSTP1, CCC GCT CCG CCC CAG TGC
TGA GTC ACG GCG CCG GCC GCT CTT CTG GAG GG;
forward MLH1, GAA CGT GAG CAC GAG GCA CTG AGG
TGA TTG GCT GAA GGC ACT TCC GTT GA; reverse
MLH1, TCA ACG GAA GTG CCT TCA GCC AAT CAC
CTC AGT GCC TCG TGC TCA CGT TG; forward p16INK4a,
GCG CTC GGC GGC TGC GGA GAG GGG GAG AGC
AGG CAG CGG GCG GCG GGG AG; reverse p16INK4a, CTC
CCC GCC GCC CGC TGC CTG CTC TCC CCC TCT CCG
CAG CCG CCG AGC GC; forward BRCA1, AAA ACT GCG
ACT GCG CGG CGT GAG CTC GCT GAG ACT TCC TGG
ACG GGG GA; and reverse BRCA1, TCC CCC GTC CAG
GAA GTC TCA GCG AGC TCA CGC CGC GCA GTC GCA
GTT TT. Oligonucleotides corresponding to natural promoter
CpG islands were obtained as fully methylated and unmethy-
lated versions. In order to perform a systematic analysis of the
in¯uence of the methyl-CpG density and spacing on binding of
MBD proteins, six different versions of the BRCA1 oligos
were obtained: a non-methylated version, a monomethylated
oligo with the methyl-CpG at the third CpG (BRCA1-M), and
two different dimethylated oligos with methyl-CpG at the
third and fourth CpGs (BRCA1-D1) or the third and sixth
positions (BRCA1-D2). Finally, two different trimethylated
oligos were obtained with the methyl-CpGs at positions 2, 3
and 4 (BRCA1-T1) or 1, 3 and 6 (BRCA1-T2) (Fig. 4E).
Forward oligonucleotides were labeled at their 5¢ ends with
6-FAM. Complementary oligonucleotides were mixed at
equimolar concentrations, and annealed by bringing the
solution to 95°C and allowing it cool down slowly to room
temperature.
Mouse MeCP2 was subcloned in pET23b from the IMAGE
clone 4948925 using NdeI and XhoI.
Construction of MBD3 mutations
The coding sequence of mouse MBD3 was ampli®ed from
pET MBD3 (4) using the following primers: sense, CAT ATG
GAG CGG AAG AGG TGG GAG; antisense, CTC GAG
CAC TCG CTC TGG CTC CGG CTC. The ampli®cation
product was T/A cloned (Topo T/A, Invitrogen) and
sequenced on both strands. The coding sequence was then
subcloned into pET21a using NdeI and XhoI. Mutations
were introduced into the resulting MBD3 pET21a clone
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by oligonucleotide-directed mutagenesis (QuickChange,
Stratagene). The following mutagenic oligonucleotides were
used: F34Y sense, GCC GGC CAC AGG GAT GTC TAT
TAC TAT AGC CCC AGC; F34Y antisense, GCT GGG GCT
ATA GTA ATA GAC ATC CCT GTG GCC GGC; H30K
sense, GGG CTG TCG GCC GGC AAA AGG GAT GTC
TTT TAC; H30K antisense, GTA AAA GAC ATC CCT TTT
GCC GGC CGA CAG CCC; H30K, F34Y sense; GGG CTG
TCG GCC GGC AAA AGG GAT GTC TAT TAC TAT AGC
CCC AGC GGG; and H30K, F34Y antisense, CCC GCT GGG
GCT ATA GTA ATA GAC ATC CCT TTT GCC GGC CGA
CAG CCC. All mutagenized clones were veri®ed by DNA
sequencing.
Puri®cation of recombinant protein
Recombinant mouse MeCP2, MBD2b and MBD3, and
Xenopus MeCP2, MBD3 and MBD3 LF were expressed in
Escherichia coli BL21 (DE3). A 500 ml aliquot of LB was
inoculated with 5 ml of an overnight culture and incubated at
37°C to an A600 of 0.7. Induction was performed by the
addition of isopropyl-b-D-thiogalactosidase to 0.5 mM and
incubation at 37°C for a further 4 h. Cells were harvested and
resuspended in 10 ml of extraction/wash buffer (50 mM
sodium phosphate pH 7.0, 300 mM NaCl, 0.1% NP-40, 1 mM
2-mercaptoethanol). Puri®cation of the soluble His-tagged
protein was performed with TALON resin (Clontech),
according to the manufacturer's protocol. Protein was
dialyzed against 20 mM Tris±HCl pH 8.0, 300 mM NaCl.
Quanti®cation was performed using the BioRad protein assay
and routinely checked by 12% SDS±PAGE.
Gel mobility shift and southwestern assays
Binding reactions for mobility shift assays were performed in
binding buffer as described by Wade et al. (5). 6-FAM-labeled
DNAs were ®rst radiolabeled. Increasing amounts of MBD
proteins were added to 6-FAM-labeled DNAs in binding
buffer [10 mM Tris-HCl pH 8.0, 3 mM MgCl2, 50 mM NaCl,
0.1 mM EDTA, 0.1% NP-40, 2 mM dithiothreitol (DTT), 5%
glycerol and 0.4 mg/ml bovine serum albumin (BSA)] and
incubated overnight at 4°C. Gel mobility shifts were per-
formed in 10% polyacrylamide gels run in 0.53 TBE buffer
(45 mM Tris pH 8.0, 45 mM boric acid, 1 mM EDTA) using
GAC or GAM1 double-stranded oligonucleotide probes. One
picomole of 6-FAM-labeled probe was mixed with puri®ed
recombinant protein, as indicated in the ®gure legends, in
10 mM Tris±HCl pH 8.0, 3 mM MgCl2, 50 mM NaCl, 0.1 mM
EDTA, 0.1% NP-40, 2 mM DTT, 5% glycerol and 0.4 mg/ml
BSA. The samples were incubated for 30 min at 37°C. A total
of 30 pmol of competitor DNA (GAC or GAM1) was used per
binding reaction. Gels were scanned on a PhosphorImager
(Molecular Dynamics). The procedure used for southwestern
assay was as described (15), except for the use of 6-FAM-
labeled oligos.
Capillary electrophoresis mobility shift assay
A neutral-coating capillary (Beckman Coulter S.A.) (32.5 cm
3 50 mm, effective length 20 cm) was used in a P/ACE MDQ
capillary electrophoresis system (Beckman Coulter S.A.)
connected to a Karat Softwareâ data-processing station. The
running buffer (40 mM Tris-borate, 0.95 mM EDTA, pH 8.0)
was chosen to provide a low current when working at high
voltage (30 kV, 923 V/cm) in order to maintain the stability of
protein±DNA complexes during separation. Laser-induced
¯uorescence (LIF) was detected by excitation at 488 nm
(3 mW argon ion laser provided by Beckman Coulter S.A.),
and emissions were collected through a 520 nm emission ®lter
(Beckman Coulter S.A.). Samples were injected under pres-
sure (0.2 p.s.i.) for 2 s and the run temperature was maintained
at 20°C. Before each run, the capillary was conditioned by
washing with running buffer for 2 min. Buffers and running
solutions were ®ltered through 0.2 mm pore-size ®lters. Three
replicates of each concentration were prepared, and each was
run twice.
Binding reactions were performed in binding buffer as
described by Wade et al. (5). Increasing amounts of all MBDs
were added to 6-FAM-labeled DNAs in binding buffer (10 mM
Tris±HCl pH 8.0, 3 mM MgCl2, 50 mM NaCl, 0.1 mM EDTA,
0.1% NP-40, 2 mM DTT, 5% glycerol and 0.4 mg/ml BSA)
and incubated overnight at 4°C.
Binding af®nities were quanti®ed by Scatchard analyses
using GraFit 3.1 software (Fig. 2). In brief, the saturation of
the oligo (R = [complex]/([complex] + [MBD])) was plotted
against increasing quantities of each MBD protein. The
concentration required for 50% saturation of binding (R1
2
) was
then calculated, seeking the best ®t of the data to different
binding models/curves.
Molecular modeling
On the basis of the close homology between different MBD
domains, models of murine MBD2- and MBD3- and Xenopus
MBD3-binding domains were developed using the NMR
structure of human MBD1 as reference, with the program
Whatif (16), following the program manual.
MBD domain boundaries were identi®ed after sequence
alignment using ClustalX (17), and the BLDPIR routine of
Whatif was used to build the models.
RESULTS AND DISCUSSION
Prior to initiating quantitative DNA binding experiments
using CEMSA, we performed classical DNA binding experi-
ments (mobility shift assays and southwestern blot analysis) to
determine whether introduction of a ¯uorescent probe altered
MBD±DNA interactions (Fig. 1). Southwestern blots were
performed with both unmethylated and methylated probes,
(GAC and GAM1; described in Materials and Methods). In
agreement with previous results (4,5), Xenopus MeCP2,
Xenopus MBD3 and murine MBD2b selectively bind
6-FAM-GAM1 (Fig. 1A, central panel). In contrast, murine
MBD3 and Xenopus MBD3 LF, a splice variant of MBD3,
with its MBD disrupted by an insertion (Fig. 1C), showed no
af®nity for this probe (Fig. 1A, central panel). No binding to
the unmethylated probe, 6-FAM-GAC, was observed in any
case (Fig. 1A, right panel). Mobility shift assays produced
results similar to the analysis by southwestern assays. As an
example, MeCP2 binding to 6-FAM-GAM1 is shown
(Fig. 1B).
MBD proteins bind to methylated DNA with
signi®cantly different af®nities
To quantitate binding of each MBD to a single methylated
CpG pair, we used a synthetic duplex oligo with 12 GAC
Nucleic Acids Research, 2003, Vol. 31, No. 6 1767
repeats, where the central CpG is methylated. The methylated
CpG pair is located at the central repeat in order to ensure that
the MBD protein establishes all the contacts required for its
correct positioning along the DNA. An unmethylated version
of this oligonucleotide was also used to evaluate non-speci®c
contributions of binding to DNA. Several proteins were
analyzed, namely Xenopus MeCP2, MBD3 and MBD3 LF,
and murine MeCP2, MBD2b and MBD3. Addition of MBD
proteins to the 6-FAM-labeled duplex oligo GAM1 produced
a discrete, sharp peak on capillary electrophoresis. Excellent
resolution of free DNA and DNA±MBD complexes was
obtained (Fig. 2A), with no gel matrix required, thus avoiding
putative caging effects on the calculated binding af®nities
(18). Under these conditions, the migration time of the free
oligo was ~4 min while for the complex it was ~5 min,
regardless of the MBD protein type. The appearance and
subsequent increase of the protein±DNA complex was con-
comitant with the decrease in the area of the peak corres-
ponding to the free probe. BSA, used as a negative control, did
not produce any retardation peak (not shown). A discrete
complex also appeared when the unmethylated oligo GAC1
was used. However, the amount of MBD protein required to
obtain a retardation peak was signi®cantly greater.
Titrations were repeated three times for each of the MBD
proteins. The results were plotted as saturation fraction against
MBD protein concentration (Fig. 2B and C). The data follow
classical saturation plots, and the protein concentrations
required for 50% saturation of binding (R1/2) were calculated
using GraFit software. We observed striking differences
among MBD proteins, particularly in the case of mammalian
MBD2b, which showed the highest af®nity for methylated
DNA (Table 1), 2.7 6 0.8 nM. In contrast, Xenopus MBD3
showed a signi®cantly lower af®nity for GAM1, 186.5 6
42.5 nM. Non-speci®c binding to the unmethylated versions of
these oligonucleotides was also observed. In fact, addition of
MBDs to the oligonucleotide resulted in the appearance of a
discrete complex, similar to that observed with methylated
DNA. However, the R1/2 values of the unmethylated oligos
were all within the same micromolar range (Fig. 2C),
indicating that the relative contribution of non-speci®c
binding was signi®cantly lower than that of speci®c inter-
action. Xenopus MBD3 LF failed to produce a retardation
peak for either methylated or unmethylated DNA.
Interestingly, the comparison of binding properties of
Xenopus MeCP2 versus murine MeCP2 indicates that the
former has a higher af®nity for the methylated probe than the
latter, indicating that minor sequence differences can result in
substantial changes in DNA binding properties. It is unlikely
that differences in af®nity could be attributed to the four
changes within the MBD sequence, namely amino acid
residues at positions 7, 31, 39 and 54 (Fig. 1C), since
structural data (19) have not assigned an essential role for any
Figure 1. Checking MBD±DNA binding analysis with 6-FAM-labeled probes by standard methods. (A) The left panel shows a Coomassie Blue-stained gel
with recombinant Xenopus MeCP2, Xenopus MBD3, Xenopus MBD3 LF, murine MBD2b and murine MBD3. The central and right panel depict a south-
western assay, with the same proteins, probed with the 6-FAM-labeled methylated oligo, GAM1 (central panel), and unmethylated oligo, GAC (right panel).
(B) Mobility shift assay with xMeCP2 and 6-FAM-labeled GAM1 DNA probe. Binding reactions were performed as described in Materials and Methods. All
lanes contain 6-FAM-labeled methylated GAM1. The ®rst lane contains only the probe, without any added protein. The subsequent lanes contain 50, 100, 200
and 200 nM xMeCP2. GAM1 (30 pmol) was added in the last lane as competitor for binding. (C) Sequence alignment of the MBD of murine MeCP2,
Xenopus MeCP2, murine MBD2 and MBD3, and Xenopus MBD3 and MBD3 LF. The positions of b-strands (arrows), loops (thick lines) and the a-helix
(rectangle), de®ned by the solution structures of MeCP2 (19) and MBD1 (22), are indicated above the alignment. General numbering for MBDs is located
above the sequence. Conserved residues are shaded, and those that proved to be essential for binding to methylated DNA are indicated with an asterisk.
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of these residues. Instead, it is possible that differences in the
binding properties of these two proteins could be due to their
differences in the sequence outside the MBD.
We also analyzed the binding properties of mammalian
MBD3. In agreement with previous observations (4), mMBD3
showed no ability to recognize methylated DNA selectively
(see Fig. 3B and C). For both the unmethylated and methylated
oligo, the retardation peak appeared only at micromolar
concentrations and the R1/2 values were very similar,
suggesting that MBD3 only interacts non-speci®cally with
DNA.
Amino acid substitutions alter the af®nity of mammalian
MBD3 for methylated DNA
Our results concerning the lack of selectivity to bind
methylated DNA by murine MBD3 can be interpreted in
terms of current structural data. On the basis of the close
homology between different MBD domains, models of murine
MBD2- and MBD3- and Xenopus MBD3 binding domains
were produced with the program Whatif (16), taking the NMR
structure of human MBD1 as reference. These structural
models shed light on the binding mechanism of different
proteins that contain MBDs. Furthermore, the models based
on the NMR structure of MBD1 support the proposed
molecular mechanism. In the case of mammalian MBD3,
the absence of binding has been attributed to the presence of
phenylalanine instead of a highly conserved tyrosine in
position 34 (20). The disruption of the hydrogen bond between
the hydroxyl group of Tyr34 and the amino group of C6 can be
observed in the model of murine MBD3 (Fig. 3A). This
change should not disturb important interactions such as that
of the guanidinium group of Arg44 with the p-electron cloud
of the aromatic ring of the amino acid in position 34, which
ensures the correct positioning of the Arg44 side chain
(Fig. 3A). However, some additional changes, due to the
presence of histidine and arginine in positions 30 and 31 in the
murine MBD3 sequence instead of the invariant lysine/
arginine and serine conserved in other MBDs, might contrib-
ute to the loss of selectivity for methylated DNA.
To test our hypothesis, we prepared point mutations of
murine MBD3 (described in Materials and Methods). In
particular, we focused on Phe34 and His30, since these
residues are the only two conserved in all MBD proteins
except for mMBD3, and prepared single mutants for each of
these residues and a double mutant form of MBD3.
Recombinant proteins were produced and puri®ed as de-
scribed above. Binding properties of the mutants were tested
by CEMSA with GAM1 and GAC oligos and compared with
Figure 2. Binding of MBD2b, xMeCP2 and MBD3 with methylated (GAM1) and unmethylated (GAC) synthetic oligos. (A) Electropherograms for mixtures
of GAM1 (24 nM) and increasing concentrations of MBD2b, xMeCP2 and MBD3 in 10 mM Tris±HCl pH 8.0, 3 mM MgCl2, 50 mM NaCl, 0.1 mM EDTA,
0.1% NP-40, 2 mM DTT, 5% glycerol and 0.4 mg/ml BSA. Analytical conditions: 32.5 cm 3 50 mm capillary (effective length 20 cm); low pressure injection
at 0.2 p.s.i. for 2 s; 20°C; 30 kV voltage; reverse polarity (anode at the detector end); buffer, 40 mM Tris-borate, 0.95 mM EDTA pH 8.0. LIF detection: exci-
tation at 488 nm, emission at 532 nm. RFU, relative ¯uorescence units. (B) Single-site ligand binding ®t for mMBD2b (white squares), xMeCP2 (white cir-
cles) and xMBD3 (black circles) with GAM1 using GraFit 3.1 software. R, saturation ([complex]/[complex] + [DNA]). [MBD], methylation binding protein
concentration. (C) Single-site ligand binding ®t for mMBD2b (white squares), xMeCP2 (white circles) and xMBD3 (black circles) with GAC using GraFit 3.1
software. R, saturation ([complex]/[complex] + [DNA]). Results in (B) and (C) are expressed as the mean 6 SD.
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wild-type MBD3. In all three mutant forms, an increase in
af®nity for methylated DNA was observed. Figure 3B shows
the appearance of the retardation peak at the same concen-
tration of each MBD3 form. Titrations for each MBD3 form
were performed as described above. The af®nity for
unmethylated probe was similar in all three mutants and
comparable with wild-type mammalian MBD3 (Fig. 3D),
indicating that the point mutations did not alter non-speci®c
binding. In contrast, the R1/2 values for methylated DNA were
decreased substantially (Fig. 3C). Both the F34Y and H30K
mutants exhibited increased selectivity for the methylated
substrate, with the F34Y mutant demonstrating marginally
improved speci®city. The double mutation (F34Y, H30K)
resulted in a small improvement in differential interaction
compared with the F34Y mutation alone (R1/2 value of 71.3
versus 80.71 nM; see Fig. 3C). These results suggest that the
tyrosine hydroxyl interaction with cytosine is crucial for
selective interaction with methylated DNA and can only be
partially compensated for by the histidine to lysine change at
position 30. Our results are in agreement with data recently
published by Saito and Ishikawa (21), which also found that
both residues H30 and F34 are responsible for the inability of
mammalian MBD3 to bind mCpG. However, in contrast to
their results, which indicate that H30K itself has no
stimulatory effect on binding of MBD3 to methylated DNA,
we observed that this single mutation is able to enhance the
speci®c binding af®nity for methylated DNA ~4.5-fold. It is
conceivable that this difference can be due to the different
separation technique employed in each case.
Surprisingly, the point mutant forms of mMBD3 had better
af®nity for methylated DNA than Xenopus MBD3. A possible
explanation for this is that xMBD3 has a deletion of the
proline residue at position 12 (see Fig. 1C). The NMR
structures of the MBDs of MeCP2 and MBD1 (19,22) show
that this residue provides a sharp turn between b-strands 1 and
2, and thus contributes to the organization of the MBD fold.
Mutations at the equivalent position (P101) in human MeCP2
have been correlated with Rett syndrome (23).
MBD proteins are in¯uenced by both sequence features
and methyl-CpG density
An additional experimental question of relevance for
MBD±DNA interactions is whether the density of methyl-
CpGs or local sequence context affect binding af®nity. We
designed oligos corresponding to four different CpG islands
that become methylated in cancer (Fig. 4D). The selected
sequences correspond to 50 bp portions of CpG islands of the
BRCA1, GSTP1, p16INK4a and MLH1 genes. These oligos
differ both in methyl-CpG density and in DNA sequence.
In CEMSA, we observed the appearance of retardation
peaks concomitant with the decrease of the free DNA peak
(Fig. 4A). Considering the resolution of this technique, the
appearance of a single peak can be interpreted as resulting
from the formation of a complex comprising one molecule
each of DNA and of protein. The incorporation of additional
molecules of MBD proteins should result in the appearance of
additional peaks, as is apparent on the addition of excess
amounts of xMeCP2 to the methylated BRCA1 DNA (Fig. 4A).
We therefore interpreted our results as representing the
formation of a single complex, even when more than one
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A subset of the primary data for these experiments is shown
in Figure 4; Table 1 shows the R1/2 values for each MBD on
each fragment. In general, the R1/2 values for methylated DNA
followed the pattern observed on the model GAM1 substrate.
MBD2b had the strongest af®nity for the substrate, reaching
half-saturation at single digit nanomolar concentrations
(Table 1). xMeCP2, mMeCP2 and xMBD3 reach half-
saturation on methylated substrates at somewhat higher
concentrations, ranging from 20 to 120 nM (Fig. 4 and
Table 1). The ability of a given MBD to discriminate between
unmethylated and methylated versions of the same DNA
fragment can be determined by calculating the ratio of the R1/2
values for unmethylated DNA divided by the same value for
methylated DNA. MBD2b displays the greatest capacity to
differentiate, with 30- to 130-fold differences between half-
saturation values for unmethylated versus methylated DNA. In
contrast, xMeCP2 and xMBD3 displayed only 5- to 20-fold
differences. Curiously enough, mMeCP2 only showed around
3-fold differences between half-saturation values for un-
methylated versus methylated oligos. The molecular basis for
this increased ability to differentiate between MBD2b and the
other three proteins currently is unclear. It has to be mentioned
that MBD2b is a minor fraction of the total MBD2 protein.
The major form of MBD2, MBD2a, contains an N-terminal
extension of 152 amino acids proximal to the MBD which may
signi®cantly affect the binding af®nity of the protein.
Two variables determine methylation density, the absolute
number of methyl-CpG pairs and how tightly they are
clustered on a given substrate. The DNA fragments used in
this study have three (MLH1), six (BRCA1 and GSTP1) or
seven (p16INK4a) methyl-CpG dinucleotides. MBD2b has
roughly equivalent af®nity for the p16INK4a and GSTP1
Figure 3. In¯uence of F34Y and H30K mutations on the DNA binding af®nity of murine MBD3. (A) Stereoview of the interaction between Tyr34 of human
MBD1 (red) and the C6 amino group of the methylated DNA (blue); PDB entry 1IG4. The model of murine MBD3 (pink) has been superimposed on the
MBD1 structure (red). The change of tyrosine/phenylalanine promotes the disruption of the hydrogen bond between the amino acid at position 34 and the
methylated C6 in the major groove. The ®gure was produced using Raster3D (29). (B) Electropherograms for mixtures of GAC DNA oligo (24 nM) and
200 nM of wild-type mMBD3, H30K, F34Y and double mutant MBD3 in 10 mM Tris±HCl pH 8.0, 3 mM MgCl2, 50 mM NaCl, 0.1 mM EDTA, 0.1%
NP-40, 2 mM DTT, 5% glycerol and 0.4 mg/ml BSA. Analytical conditions as in Figure 2A. RFU, relative ¯uorescence units. (C) Single-site ligand binding
®t for mMBD3 (white circles), F34Y (black circles), H30K (white squares) and double mutant (black squares) with the synthetic oligo GAM1 using GraFit
3.1 software. R, saturation ([complex]/[complex] + [DNA]). Results are expressed as mean 6 SD. Analytical conditions are as described in Figure 2A.
(D) Single-site ligand binding ®t for wild-type MBD3 (white circles), F34Y (black circles), H30K (white squares) and double mutant (black squares) with the
synthetic oligo GAC using GraFit 3.1 software. R, saturation ([complex]/[complex] + [DNA]). Results are expressed as mean 6 SD. Analytical conditions as
described in Figure 2A. (E) R1/2 values for wild-type mMBD3, H30K, F34Y and double mutant MBD3 and synthetic oligos GAM1 and GAC forms
calculated by ®tting the data obtained from R-CEMSA to non-cooperative binding. Results are expressed as mean 6 SD. Values are expressed in molar units
and are multiplied by 109.
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fragments, with the lowest af®nity for MLH1, the fragment
with the fewest methyl-CpG pairs (Table 1). xMeCP2, on the
other hand, had the highest af®nity for the BRCA1 fragment,
followed by GSTP1, p16INK4a and MLH1. Finally, xMBD3
preferred GSTP1, followed by BRCA1, p16INK4a and MLH1. It
is thus apparent that the absolute number of CpGs affects
binding af®nity, as expected. MLH1 has roughly half the
number of methyl-CpGs and is the poorest substrate for all
three proteins.
It is informative to compare the R1/2 values of these MBD
proteins for the two fragments with the same number of
methyl-CpGs, GSTP1 and BRCA1. MBD2b, mMeCP2 and
xMBD3 bind more avidly to GSTP1, while xMeCP2 binds
better to BRCA1 (Table 1). Differences in af®nity for these
two fragments with the same number of CpGs could be due to
two different effects, local sequence or CpG distribution.
In order to assess the relative effects of methyl-CpG spacing
and density in the context of a natural sequence in a more
systematic manner, we prepared ®ve different oligos with the
BRCA1 sequence in which one, two or three of its CpG
dinucleotides were methylated with different spacing
(Fig. 4E). Figure 4F summarizes the results obtained with
the ®ve differentially methylated BRCA1 oligos and the two
versions of MeCP2. We observed that xMeCP2 and mMeCP2
have a lower af®nity for any of the partially methylated
BRCA1 oligos than the af®nity observed for the fully
methylated BRCA1 oligo (Table 1). This result supports the
notion that the absolute number of CpGs affects binding.
Furthermore, although only small differences were observed
among the different partially methylated BRCA1 oligos,
ranging within 2-fold, the behavior of both Xenopus and
mouse MeCP2 was similar, suggesting that these differences
Figure 4. Binding of xMeCP2 and MBD3 with synthetic methylated human CpG islands. (A) Electropherograms for mixtures of BRCA1 DNA oligo (24 nM)
and increasing concentrations of xMeCP2 in 10 mM Tris±HCl pH 8.0, 3 mM MgCl2, 50 mM NaCl, 0.1 mM EDTA, 0.1% NP-40, 2 mM DTT, 5% glycerol
and 0.4 mg/ml BSA. Analytical conditions as in Figure 2A. RFU, relative ¯uorescence units. (B) Single-site ligand binding ®t for xMeCP2 with synthetic
oligos corresponding to the promoter region of BRCA1 (white circles), p16INK4a (black circles), MLH1 (white squares) and GSTP1 (black triangles) using
GraFit 3.1 software. R, saturation ([complex]/[complex] + [DNA]). Results are expressed as mean 6 SD. Analytical conditions as described in Figure 2A.
(C) Single-site ligand binding ®t for xMBD3 with synthetic oligos corresponding to the promoter region of BRCA1, p16INK4a, MLH1 and GSTP1. Symbols as
in (B). (D) Schematic representation of the location of methylcytosines (black circles) in the synthetic oligos BRCA1, p16INK4a, MLH1 and GSTP1.
(E) Schematic representation of the location of methylcytosines (black circles) in the synthetic oligos BRCA1-M, BRCA1-D1, BRCA1-D2, BRCA1-T1 and
BRCA1-T2. A base pair scale is shown at the bottom. A vertical bar lacking a black circle shows the location of an unmethylated CpG. (F) R1/2 values for
Xenopus (x) (blue bar) and mammalian (m) (orange bar) MeCP2 and synthetic oligos BRCA1-M, BRCA1-D1, BRCA1-D2, BRCA1-T1 and BRCA1-T2
calculated by ®tting the data obtained from R-CEMSA to non-cooperative binding behavior using GraFit software. Results are expressed as mean 6 SD.
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were signi®cant. The poorest af®nity observed for both
xMeCP2 and mMeCP2 was obtained with the dimethylated
oligo with the shortest spacing (BRCA1-D1). It is possible that
the existence of an additional methyl-CpG within the 12 bp
protected by the MBD (24) acts as a discouraging feature for
binding.
Finally, our results do not allow local sequence effects on
af®nity to be ruled out. However, the binding af®nities of
MeCP2 for monomethylated oligos (GAM1 and BRCA1-M)
and trimethylated oligos (MLH1 and BRCA1-T2) were
virtually identical regardless of the sequence, suggesting that
at least in the above examples no sequence effects occur.
The major conclusions of this work are consistent with the
likelihood that, at least in some instances, the binding
properties of a given MBD protein can in¯uence its targeting
to a speci®c locus. We have observed that small sequence
differences in the MBD domain are manifested in rather
striking changes in DNA recognition properties. The ®nding
that the F34Y mutant version of mMBD3 selectively
recognizes methylated DNA signi®cantly better than
xMBD3 strongly supports this notion. We also observed
that, on naturally occurring sequences, increases in the total
number of methyl-CpG pairs resulted in increased binding
af®nity. Of course, increasing the total number of methyl-
CpGs per fragment serves to increase the number of available
binding sites. Most interesting of all, there appears to be an
additional determinant of binding af®nity related to either the
spacing of methyl CpGs or to local sequence context.
Whatever the molecular determinants of the differences
observed in this work, they suggest that MBD proteins are
likely to be differentially localized within the genome, at least
in part, as a direct re¯ection of their inherent binding
preferences.
Obviously, additional factors associated with MBD com-
plexes should be involved in their speci®c recruitment to
particular promoters. Therefore, based on our data, it seems
that all potential substrates will bind MBD2 in preference to
other MBD proteins. However, this is not the situation in vivo.
Additional factors (the N-terminal extension in MBD2a, other
proteins complexed to the MBD proteins; chromatin context)
may well have effects in vivo. The current results concerning
the targeting of MBD to hypermethylated promoters support
this model. In fact, the speci®c association of the MBD
complex with diverse loci has been demonstrated in a few
cases (7±9). Although determinants of speci®c targeting
remain unknown, sequence-speci®c transcription factors are
likely to be involved in the selective recruitment of MBD-
containing complexes by interaction with any of their
subunits. For instance, Drosophila Mi-2, a component of a
¯y MBD-containing complex, interacts with the Hunchback
transcriptional repressor, which binds directly to regulatory
sequences of HOX genes (25). Also, the zinc ®nger protein
Ikaros interacts with Mi-2 in erythroid cells (26). The
observation that dMBD-like, the Drosophila MBD2/3 homo-
log, which is unable to bind methylated DNA, is associated
with discrete loci suggests that this protein is targeted within
the genome by interactions with sequence-speci®c DNA
binding proteins (27).
The overall picture can accommodate not only speci®c
targeting but also partial redundancy. Fine-scale regulation of
the expression levels of MBD proteins may contribute to the
selection of the MBD complex involved in the repression at
speci®c sites (28). Differences in the af®nity of different MBD
proteins for methylated DNA, as demonstrated in the current
study, must surely play a role in the selective recruitment of
MBDs to promoters.
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